Beauty Health Co. Announces Director Changes and CEO Compensation

TL;DR

Beauty Health Co. board shakeup: Director out, new director in, CEO compensation deal struck.

AI Summary

On October 8, 2024, The Beauty Health Company announced the departure of Director Andrew C. Chang and the appointment of Dr. Vivian Lee as a new director. Additionally, the company entered into a new compensatory arrangement with its Chief Executive Officer, Michael J. Moschner. The filing does not specify dollar amounts or further details on the compensatory arrangement.

Why It Matters

Changes in board composition and executive compensation arrangements can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Director departures and new compensation arrangements can introduce uncertainty regarding leadership stability and future strategic direction.

Key Players & Entities

• Andrew C. Chang (person) — Departing Director
• Dr. Vivian Lee (person) — Newly Appointed Director
• Michael J. Moschner (person) — Chief Executive Officer
• The Beauty Health Company (company) — Registrant
• October 8, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.0001 — tered Class A Common Stock, par value $0.0001 per share SKIN The Nasdaq Capital Marke

Filing Documents

• skin-20241008.htm (8-K) — 28KB
• 0001628280-24-042835.txt ( ) — 180KB
• skin-20241008.xsd (EX-101.SCH) — 2KB
• skin-20241008_def.xml (EX-101.DEF) — 15KB
• skin-20241008_lab.xml (EX-101.LAB) — 26KB
• skin-20241008_pre.xml (EX-101.PRE) — 15KB
• skin-20241008_htm.xml (XML) — 3KB

From the Filing

skin-20241008 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2024 The Beauty Health Company (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 2165 Spring Street Long Beach , CA (Address of principal executive offices) 90806 (Zip Code) ( 800 ) 603-4996 (Registrant's telephone number, including area code) Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Class A Common Stock, par value $0.0001 per share SKIN The Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 ( 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ( 240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Chief Revenue Officer Departure On October 8, 2024, the Board of Directors (the "Board") of The Beauty Health Company (the "Company") terminated Daniel Watson's employment as Chief Revenue Officer of the Company without cause, effective as of October 14, 2024. Mr. Watson will remain employed with the Company in an advisory role until no later than December 31, 2024. Mr. Watson's termination is not a result of any disagreement with the Company on any matter relating to the Company's financial reporting, operations, policies or practices. The Company intends to enter into a separation agreement with Mr. Watson as soon as practicable in connection with his separation as Chief Revenue Officer of the Company that will document any applicable payments or benefits to be provided to him in respect of such separation. The Company will file an amendment to this Current Report on Form 8-K within four business days after the parties enter into a definitive separation agreement. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 15, 2024 The Beauty Health Company By: /s/ Michael Monahan Name: Michael Monahan Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR